BioSpace News Archive

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that its Board of Directors has appointed Brad Nagel as the Company’s Chief Financial Officer, effective November 14, 2022.

Sagimet Biosciences, a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, announced that it has appointed David Happel as chief executive officer, replacing George Kemble, PhD, who will transition to become executive chairman of the board.

CMP Pharma announced today that Tadliq ® (Tadalafil) Oral Suspension, 20 mg/5 mL, the first and only FDA-approved oral liquid suspension of tadalafil, is now available.

Catholic Health’s Mercy Hospital has appointed Tommaso Addona, MD, FACS to Chief of Plastic Surgery. Dr. Addona also holds the title of Chief of Plastic Surgery at St. Joseph Hospital in Bethpage, NY.

Nashville Biosciences today announced expanding its offerings to include radiologic imaging data as a new product offering.

Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, today announced the addition of Raymond Falci to its investment team.

University of Michigan research team is first to perform virtual clinical trials using a multi-scale lung model, with early results expected next year

Scientists at deCODE genetics, a subsidiary of Amgen, publish a large genome-wide association study on nonalcoholic fatty liver disease in Nature Genetics.

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced a license and collaboration agreement with Griffith University in Queensland, Australia, to develop vaccines that prevent diseases with significant unmet medical need caused by emerging antibiotic resistant strains.

Transcenta Holding Limited announces that Transcenta is invited to participate the 10th TEMTIA meeting in Paris, France, November 7 to 10 and present preclinical data of TST003, Transcenta’s first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1.